Physician profile
Courtney M Burns
NPI 1447512579
$4,189.68
in general payments reported to CMS, 2019-2025
24 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 90% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $702 · 2023: $784 · 2024: $720 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $632.72 | 2022-2025 | |
| Pfizer INC. | $611.74 | 2021-2025 | |
| Amgen INC. | $602.34 | 2022-2025 | Repatha, Repatha |
| Cvrx, INC. | $495.44 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $251.26 | 2021-2025 | Farxiga, Wainua |
| Abbott Laboratories | $208.48 | 2022-2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $182.55 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $169.95 | 2022-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $167.58 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $138.37 | 2021-2023 | Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.38 | 2021-2022 | |
| Edwards Lifesciences Corporation | $116.64 | 2021 | |
| Alnylam Pharmaceuticals INC. | $109.76 | 2023-2025 | Onpattro, Amvuttra |
| Regeneron Healthcare Solutions, INC. | $66.36 | 2024-2025 | Evkeeza |
| Boston Scientific Corporation | $59.16 | 2024-2025 | Watchman Flx, Watchman |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $54.22 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $50.43 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $45.52 | 2024-2025 | Uptravi, Opsumit |
| Bridgebio Pharma, INC. | $45.10 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $15.99 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Glaxosmithkline, LLC. | $13.63 | 2023 | Shingrix, Bexsero |
| Amarin Pharma, INC. | $12.02 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3.04 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.